Literature DB >> 30640659

Self-reported cumulative medical opioid exposure and subjective responses on first use of opioids predict analgesic and subjective responses to placebo-controlled opioid administration.

Stephen Bruehl1, Amanda L Stone2,3, Cassandra Palmer2, David A Edwards2, Asokumar Buvanendran4, Rajnish Gupta2, Melissa Chont2, Mary Kennedy5, John W Burns5.   

Abstract

BACKGROUND AND OBJECTIVES: To expand the evidence base needed to enable personalized pain medicine, we evaluated whether self-reported cumulative exposure to medical opioids and subjective responses on first opioid use predicted responses to placebo-controlled opioid administration.
METHODS: In study 1, a survey assessing cumulative medical opioid exposure and subjective responses on first opioid use was created (History of Opioid Medical Exposure (HOME)) and psychometric features documented in a general sample of 307 working adults. In study 2, 49 patients with chronic low back pain completed the HOME and subsequently rated back pain intensity and subjective opioid effects four times after receiving saline placebo or intravenous morphine (four incremental doses) in two separate double-blinded laboratory sessions. Placebo-controlled morphine effects were derived for all outcomes.
RESULTS: Two HOME subscales were supported: cumulative opioid exposure and euphoric response, both demonstrating high test-retest reliability (Intraclass Correlation Coefficients > 0.93) and adequate internal consistency (Revelle's Omega Total = 0.73-0.77). In study 2, higher cumulative opioid exposure scores were associated with significantly greater morphine-related reductions in back pain intensity (p=0.02), but not with subjective drug effects. Higher euphoric response subscale scores were associated with significantly lower overall perceived morphine effect (p=0.003), less sedation (p=0.04), greater euphoria (p=0.03) and greater desire to take morphine again (p=0.02). DISCUSSION: Self-reports of past exposure and responses to medical opioid analgesics may have utility for predicting subsequent analgesic responses and subjective effects. Further research is needed to establish the potential clinical and research utility of the HOME. TRIAL REGISTRATION NUMBER: NCT02469077. © American Society of Regional Anesthesia & Pain Medicine 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  analgesic; chronic pain; misuse; opioid; questionnaire; subjective effects

Mesh:

Substances:

Year:  2019        PMID: 30640659     DOI: 10.1136/rapm-2018-000008

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  4 in total

1.  Development and Validation of a Model to Predict Postdischarge Opioid Use After Cesarean Birth.

Authors:  Sarah S Osmundson; Alese Halvorson; Kristin N Graves; Clara Wang; Stephen Bruehl; Carlos G Grijalva; Dan France; Katherine Hartmann; Shilpa Mokshagundam; Frank E Harrell
Journal:  Obstet Gynecol       Date:  2022-04-05       Impact factor: 7.623

2.  Retrospectively assessed subjective effects of initial opioid use differ between opioid misusers with opioid use disorder (OUD) and those who never progressed to OUD: Data from a pilot and a replication sample.

Authors:  Arpana Agrawal; Paul W Jeffries; A Benjamin Srivastava; Vivia V McCutcheon; Michael T Lynskey; Andrew C Heath; Elliot C Nelson
Journal:  J Neurosci Res       Date:  2020-05-28       Impact factor: 4.164

3.  The association between endogenous opioid function and morphine responsiveness: a moderating role for endocannabinoids.

Authors:  Stephen Bruehl; John W Burns; Amanda Morgan; Kelli Koltyn; Rajnish Gupta; Asokumar Buvanendran; David Edwards; Melissa Chont; Philip J Kingsley; Larry Marnett; Amanda Stone; Sachin Patel
Journal:  Pain       Date:  2019-03       Impact factor: 7.926

4.  Greater Conditioned Pain Modulation Is Associated With Enhanced Morphine Analgesia in Healthy Individuals and Patients With Chronic Low Back Pain.

Authors:  Stephen Bruehl; Christopher R France; Amanda L Stone; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; John W Burns
Journal:  Clin J Pain       Date:  2021-01       Impact factor: 3.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.